Assigning the proper class to a medical device (MD) is one of the most important activities carried out by a manufacturer. The Medical Device Coordination Group (MDCG) (1) released guideline MDCG 2021-244 (2) in October, providing clarification on how medical devices (MDs) should be classified under the Medical Device Regulation (MDR) 2017/745.
The MD manufacturer is responsible for assigning the proper classification to its MD, as it depends on the product’s claims and functionalities. Incorrectly classifying a MD could significantly impact product development, considering different regulatory, nonclinical, and clinical requirements depend on the classification.
The MDCG issued this guidance to clarify the classification system under MDR and allow for easier comprehension of the MD classifications. The guidance includes a stepwise flowchart (3) illustrating how each rule should be applied and providing practical examples.
In the EU, MDs are sorted into four different classes, from low to high risk:
Classification is based on a risk level system that considers the degree of invasiveness, the part of the body affected, the contact duration with the body, and other elements. These elements, along with the intended use of the device, should help manufacturers determine which “classification rules” apply to their device.
If more than one rule applies, the manufacturer should assign the highest risk class to the device. For example, if both Rule X (Class IIb) and Rule Y (Class III) apply to the device, the device would be assigned the higher one: Class III.
If the regulatory classification of the device is not clear, or it could be controversial, Alira Health recommends seeking out clarification. Particularly with borderline products, e.g., products that could be seen as medicinal, cosmetics, or food supplements, clarification is important as not properly categorizing the product may have important consequences for its development.
The Alira Health Regulatory team provides support to manufacturers on:
Learn more about our regulatory support.
Subscribe to our newsletter for the latest news, events, and thought leadership